TheraBiogen Inc. fka TRAB

[pm071]

THERABIOGEN, INC. INKS DEAL WITH MIAMI HEAT AND WALGREENS
E-mail

Partnership Will Focus on TheraMax® Cold and Flu Relief
and Allergy Relief Products

New York, New York--(February 17, 2011) - TheraBiogen, Inc. (OTC BB: TRAB) announced today that it has entered into a partnership with the Miami HEAT and South Florida Walgreens.

Through a relationship with JumpStart, Inc., TheraMax® was chosen as an official partner of a program between the Miami HEAT and Walgreens. The program will encompass product sales and promotions in Walgreens pharmacies in South Florida as well as joint promotion on select Miami HEAT advertising and marketing assets.
TheraBiogen has been selling TheraMax® Cold & Flu Relief and TheraMax® Allergy Relief since the beginning of the 2010 Fall Season for cold and flu relief. TheraMax® products are homeopathic nasal sprays that do not contain zinc.
“We are very excited to team up with the HEAT and Walgreens on this opportunity,” said Kelly Hickel, CEO of TheraBiogen, Inc. “This will make more consumers aware of our products and provide an important product to Walgreens customers. As we expand our presence in South Florida Walgreens, we expect to see the same great support from consumers that we have seen since our national launch in October of last year.”
TheraMax® has been approved for sale and is now available in over 300 South Florida Walgreens locations. For more information on TheraMax go to www.theramaxrelief.com.
About TheraBiogen, Inc.
TheraBiogen, Inc. is the manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing?nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company’s most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.

Company Contact:
TheraBiogen, Inc.
Kelly T. Hickel, Chairman and CEO
646-808-3095
[e-mail] e-mail address is being protected from spambots. You need JavaScript enabled to view it